Hanlim Pharm. Co., Ltd.   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Seoul Korea, Republic of (1974)
Status: No NME R&D (1974)

Organization Overview

First Clinical Trial
2009
NCT01806792
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Hanlim Pharm. Co., Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Disease (Phase 2)

Arthritis (Phase 2)

Arthritis, Rheumatoid (Phase 2)

Breast Diseases (Phase 3)

Bronchitis (Phase 2)

Bronchitis, Chronic (Phase 2)

Diabetic Retinopathy (Phase 4)

Dry Eye Syndromes (Phase 3)

Dyslipidemias (Phase 3)

Essential Hypertension (Phase 4)

Eye Diseases (Phase 3)

Glaucoma (Phase 4)

Hypercholesterolemia (Phase 3)

Hypertension (Phase 4)

Keratoconjunctivitis Sicca (Phase 3)

Lung Neoplasms (Phase 2)

Osteoarthritis (Phase 3)

Osteoarthritis, Knee (Phase 3)

Osteoporosis (Phase 4)

Pneumonia (Phase 2)

Pruritus (Phase 3)

Radiation Pneumonitis (Phase 2)

Retinal Diseases (Phase 4)

Rhinitis (Phase 3)

Rhinitis, Allergic (Phase 3)

Rhinitis, Allergic, Perennial (Phase 3)

Urticaria (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 42
  • # of Trial APIs: 30